Actuate Therapeutics is a private biopharmaceutical company focused on the development of compounds for use in the treatment of cancer, and inflammatory diseases leading to fibrosis and neurodegeneration.
Actuate Therapeutics focuses is on the development of compounds for combination use in high impact carcinomas including glioblastoma, ovarian, breast, and pancreatic cancers.
Actuate was founded in 2015 and is headquartered in Fort Worth, Texas, with an office in Dublin, Ireland.
Actuate Therapeutics is on a mission of discovering, developing, and commercializing new agents that target GSK-3β, based on intellectual capital developed in the laboratories. The company is advancing research for the development of our compounds for the treatment of inflammation leading to fibrosis and neurodegeneration, where results of early studies in animal models are promising.
Actuate Therapeutics is backed by Bios Partners, Kairos Ventures, DEFTA Partners and others. The company raised $6.5M in a Series B-3 financing on Nov 12, 2019, bringing total funding for Series B round to over $28.2M. And brings Actuate's total funding to $31.2M to date.